sRAGE, pg/mL Pentosidinepg/mL AOPPs (μmol/l)
r P-value r P-value r P-value
Age (years) 0.16 0.25 0.09 0.53 0.14 0.31
Duration 0.14 0.32 0.23 0.10 0.22 0.11
Fasting blood glucse (mg/dl) 0.33 0.01* 0.39 0.005* 0.28 0.04*
2-h PP blood glucose  (mg/dl) 0.39 0.005* 0.28 0.04* 0.28 0.04
HDL (mg/dl) -0.02 0.87 -0.25 0.07 -0.01 0.90
TAG (mg/dl) 0.06 0.66 0.25 0.07 0.26 0.06
TC (mg/dl) 0.40 0.004* 0.29 0.04* 0.33 0.01*
LDL (mg/dl) 0.64 0.001* 0.28 0.04* 0.60 0.001*
Fasting insulin (μIU/ml) 0.36 0.009* 0.62 0.000* 0.56 0.001*
HOMA-IR 0.46 0.001* 0.56 0.000* 0.62 0.001*
UACR 0.15 0.28 0.04 0.78 0.05 0.71
Urea (mg %) 0.51 0.000* 0.30 0.03* 0.11 0.42
Serum creatinine (mg/dl) 0.34 0.015* 0.32 0.02* 0.06 0.64
estimated GFR (eGFR ,ml/min per 1.73m2) -0.12 0.39 -0.17 0.21 -0.08 0.58
sRAGE, pg/mL     0.63 0.001* 0.52 0.001*
Pentosidinepg/mL 0.63 0.001*     0.59 0.001*
AOPPs 0.52 0.001* 0.59 0.001*    
r= Pearson’s correlation coefficient, P was considered significant at <0.05.; *Significant HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, sRAGE: soluble receptor for advanced glycation end-products, AOPP:advanced oxidation protein products
Table 6: showed Pearson’s correlation between serum levels of sRAGE, Pentosidine and AOPP with other studied parameters in diabetic patient groups.